Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY PMDA Strengthens Consultation System to Support Biomarker Development
April 3, 2012
-
REGULATORY DPJ’s PAL Subcommittee to Hold Off Final Recommendation on PAL Amendment Until Late April
April 2, 2012
-
REGULATORY MHLW Proposes Pricing of Long-Listed Products to Be Concluded in FY2013: CSIMC Meeting
March 30, 2012
-
BUSINESS Fujifilm, Kyowa Hakko Kirin Establish JV to Develop Biosimilars
March 29, 2012
-
BUSINESS Astellas to Place Greater Importance on China Business: Executive Katayanagi
March 28, 2012
-
REGULATORY Use of Medicoeconomic Assessment in Drug Pricing “Unrealistic”: DG for Policy Planning and Evaluation Katori
March 28, 2012
-
REGULATORY Council for Improvement of the Distribution of Ethical Drugs Agrees to Establish Working Team, Focus on Spreading “Mutual Understanding”
March 27, 2012
-
REGULATORY Council Approves 80 Development Requests from 2nd Round
March 27, 2012
-
BUSINESS Epadel Generic in Short Supply at Sawai Pharmaceutical Due to Promotional Measures
March 26, 2012
-
BUSINESS Break of Day－Working to Optimize Settai Practices, Increase Financial Transparency: 3
March 26, 2012
-
BUSINESS Bayer Yakuhin to Initiate Drug Use-Result Survey on 10,000 Patients for Xarelto
March 23, 2012
-
BUSINESS Astellas Vice Deputy Chairman Ishii Says Company R&D Strategy Focused on Personalized Medicine
March 22, 2012
-
REGULATORY Council Meeting Considers Working Team to Explore Directions for Drug Distribution Improvement
March 21, 2012
-
ORGANIZATION Asia Partnership Conference Starts Talks for Early NDA Approval at Inauguration Meeting in Tokyo
March 19, 2012
-
BUSINESS Break of Day－Working to Optimize Settai Practices, Increase Financial Transparency: 1
March 19, 2012
-
BUSINESS Eli Lilly Japan Looks at Double-Digit Growth Despite Large Price Cuts in 2 Mainstay Drugs: President Zulueta
March 16, 2012
-
ORGANIZATION JPMA Compiles Policies for Transparency in Patient Group Relationships, Disclosure for States of Donations
March 15, 2012
-
BUSINESS Sawai’s Next Midterm Management Plan Aims to Create a “Muscular Company”: Pres. Sawai
March 14, 2012
-
BUSINESS Pfizer Reports 19% Boost in Sales in FY2011, “Continued Growth Possible” After Re-Pricing
March 13, 2012
-
REGULATORY Convincing Data Needed to Perpetuate Premium for New Drug Development: Mr Yoshida of MED
March 13, 2012
ページ
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…